
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Preclinical |
Laboratories of 1 Biomedical Magnetic Resonance, 2 Medicinal Chemistry and Radiopharmacy, and 3 Pharmacology and Therapeutics and 4 Radiobiology and Radioprotection Unit, Université Catholique de Louvain, Brussels, Belgium
Requests for reprints: Bernard Gallez, CMFA/REMA Units, Université Catholique de Louvain, Avenue E. Mounier 73.40, B-1200 Brussels, Belgium. Phone: 32-2-7642792; Fax: 32-2-7642790; E-mail: Gallez{at}cmfa.ucl.ac.be.
Purpose: The aim of this work was to study changes in the tumor microenvironment early after an antiangiogenic treatment using thalidomide (a promising angiogenesis inhibitor in a variety of cancers), with special focus on a possible "normalization" of the tumor vasculature that could be exploited to improve radiotherapy.
Experimental Design: Tumor oxygenation, perfusion, permeability, interstitial fluid pressure (IFP), and radiation sensitivity were studied in an FSAII tumor model. Mice were treated by daily i.p. injection of thalidomide at a dose of 200 mg/kg. Measurements of the partial pressure of oxygen (pO2) were carried out using electron paramagnetic resonance oximetry. Three complementary techniques were used to assess the blood flow inside the tumor: dynamic contrast-enhanced magnetic resonance imaging, Patent Blue staining, and laser Doppler imaging. IFP was measured by a "wick-in-needle" technique.
Results: Our results show that thalidomide induces tumor reoxygenation within 2 days. This reoxygenation is correlated with a reduction in IFP and an increase in perfusion. These changes can be attributed to extensive vascular remodeling that we observed using CD31 labeling.
Conclusions: In summary, the microenvironmental changes induced by thalidomide were sufficient to radiosensitize tumors. The fact that thalidomide radiosensitization was not observed in vitro, and that in vivo radiosensitization occurred in a narrow time window, lead us to believe that initial vascular normalization by thalidomide accounts for tumor radiosensitization.
Key Words: antiangiogenic oxygen flow interstitial fluid pressure radiotherapy
This article has been cited by other articles:
![]() |
J. DeWever, F. Frerart, C. Bouzin, C. Baudelet, R. Ansiaux, P. Sonveaux, B. Gallez, C. Dessy, and O. Feron Caveolin-1 Is Critical for the Maturation of Tumor Blood Vessels through the Regulation of Both Endothelial Tube Formation and Mural Cell Recruitment Am. J. Pathol., November 1, 2007; 171(5): 1619 - 1628. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Duda, R. K. Jain, and C. G. Willett Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers J. Clin. Oncol., September 10, 2007; 25(26): 4033 - 4042. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P.M. Dings, M. Loren, H. Heun, E. McNiel, A. W. Griffioen, K. H. Mayo, and R. J. Griffin Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization Clin. Cancer Res., June 1, 2007; 13(11): 3395 - 3402. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mannheim, D. Versari, E. Daghini, M. Gossl, O. Galili, A. Chade, V. S. Rajkumar, E. L. Ritman, L. O. Lerman, and A. Lerman Impaired myocardial perfusion reserve in experimental hypercholesterolemia is independent of myocardial neovascularization Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2449 - H2458. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Jain, R. T. Tong, and L. L. Munn Effect of Vascular Normalization by Antiangiogenic Therapy on Interstitial Hypertension, Peritumor Edema, and Lymphatic Metastasis: Insights from a Mathematical Model Cancer Res., March 15, 2007; 67(6): 2729 - 2735. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Crokart, B. F. Jordan, C. Baudelet, G. O. Cron, J. Hotton, K. Radermacher, V. Gregoire, N. Beghein, P. Martinive, C. Bouzin, et al. Glucocorticoids Modulate Tumor Radiation Response through a Decrease in Tumor Oxygen Consumption Clin. Cancer Res., January 15, 2007; 13(2): 630 - 635. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Horsman and D. W. Siemann Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies Cancer Res., December 15, 2006; 66(24): 11520 - 11539. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ansiaux, C. Baudelet, B. F. Jordan, N. Crokart, P. Martinive, J. DeWever, V. Gregoire, O. Feron, and B. Gallez Mechanism of Reoxygenation after Antiangiogenic Therapy Using SU5416 and Its Importance for Guiding Combined Antitumor Therapy Cancer Res., October 1, 2006; 66(19): 9698 - 9704. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Martinive, J. De Wever, C. Bouzin, C. Baudelet, P. Sonveaux, V. Gregoire, B. Gallez, and O. Feron Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol. Cancer Ther., June 1, 2006; 5(6): 1620 - 1627. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hassid, E. Furman-Haran, R. Margalit, R. Eilam, and H. Degani Noninvasive magnetic resonance imaging of transport and interstitial fluid pressure in ectopic human lung tumors. Cancer Res., April 15, 2006; 66(8): 4159 - 4166. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Yance Jr and S. M. Sagar Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther, March 1, 2006; 5(1): 9 - 29. [Abstract] [PDF] |
||||
![]() |
R. Ansiaux, C. Baudelet, G. O. Cron, J. Segers, C. Dessy, P. Martinive, J. De Wever, J. Verrax, V. Wauthier, N. Beghein, et al. Botulinum Toxin Potentiates Cancer Radiotherapy and Chemotherapy Clin. Cancer Res., February 15, 2006; 12(4): 1276 - 1283. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Cairns, I. Papandreou, and N. Denko Overcoming Physiologic Barriers to Cancer Treatment by Molecularly Targeting the Tumor Microenvironment Mol. Cancer Res., February 1, 2006; 4(2): 61 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kaliski, L. Maggiorella, K. A. Cengel, D. Mathe, V. Rouffiac, P. Opolon, N. Lassau, J. Bourhis, and E. Deutsch Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion Mol. Cancer Ther., November 1, 2005; 4(11): 1717 - 1728. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Crokart, K. Radermacher, B. F. Jordan, C. Baudelet, G. O. Cron, V. Gregoire, N. Beghein, C. Bouzin, O. Feron, and B. Gallez Tumor Radiosensitization by Antiinflammatory Drugs: Evidence for a New Mechanism Involving the Oxygen Effect Cancer Res., September 1, 2005; 65(17): 7911 - 7916. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |